Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Acadia Pharmaceuticals

Acadia Pharmaceuticals (NASDAQ: ACAD) insider transactions

In the twelve months to 10 November 2026, executives and directors of Acadia Pharmaceuticals reported 24 open-market sales of 114,962 shares ($2.8m) and 0 open-market purchases, by 5 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Acadia Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
30 October 2026Schneyer Mark C.EVP, Chief Financial OfficerOpen-market sale−3,321$20.8871,322Form 4
15 October 2026Schneyer Mark C.EVP, Chief Financial OfficerGrant or award+6,815—74,643Form 4
6 August 2026Schneyer Mark C.EVP, Chief Financial OfficerOption exercise, 10b5-1 plan+14,292$17.8482,120Form 4
6 August 2026Schneyer Mark C.EVP, Chief Financial OfficerOpen-market sale, 10b5-1 plan−5,000$29.0077,120Form 4
6 August 2026Schneyer Mark C.EVP, Chief Financial OfficerOpen-market sale, 10b5-1 plan−9,292$29.3467,828Form 4
5 August 2026Schneyer Mark C.EVP, Chief Financial OfficerOption exercise, 10b5-1 plan+5,849$17.8473,677Form 4
5 August 2026Schneyer Mark C.EVP, Chief Financial OfficerOpen-market sale, 10b5-1 plan−5,849$29.0067,828Form 4
30 July 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevOpen-market sale−16,508$26.1319,044Form 4
30 July 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevOpen-market sale−50$26.1718,994Form 4
29 July 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevOption exercise+32,272—35,552Form 4
26 June 2026Kihara JamesPrincipal Accounting OfficerOpen-market sale, 10b5-1 plan−11,421$26.0813,088Form 4
29 May 2026Baker Brothers Life Sciences LPDirectorGrant or award+18,622—3,677,357Form 4
29 May 2026Baker Brothers Life Sciences LPDirectorGrant or award+18,622—39,384,587Form 4
29 May 2026Harrigan EdmundDirectorOption exercise+8,107—43,148Form 4
29 May 2026Brege LauraDirectorOption exercise+8,107—23,202Form 4
29 May 2026Daly James MDirectorOption exercise+8,107—12,148Form 4
29 May 2026Poole JonathanDirectorOption exercise+2,010—2,010Form 4
29 May 2026Garofalo Elizabeth A.DirectorOption exercise+8,107—33,489Form 4
29 May 2026Ndu AdoraDirectorOption exercise+8,107—32,908Form 4
26 May 2026Kihara JamesPrincipal Accounting OfficerOpen-market sale−5,401$21.1824,509Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Acadia Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.